<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T02:57:03Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/13689" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/13689</identifier><datestamp>2025-09-30T02:07:32Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:DIDLInfo>
      <dcterms:created xmlns:dcterms="http://purl.org/dc/terms/" xsi:schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2025-09-30T02:07:32Z</dcterms:created>
   </d:DIDLInfo>
   <d:Item id="hdl_11351_13689">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:11351/13689</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma</dc:title>
               <dc:creator>BAURAIN, JEAN-FRANCOIS</dc:creator>
               <dc:creator>Martelli, Serena</dc:creator>
               <dc:creator>Arntz, Ramon</dc:creator>
               <dc:creator>Savoia, Paola</dc:creator>
               <dc:creator>MUÑOZ COUSELO, EVA</dc:creator>
               <dc:creator>Berking, Carola</dc:creator>
               <dc:subject>Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris</dc:subject>
               <dc:subject>Carcinoma basocel·lular - Tractament</dc:subject>
               <dc:subject>DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Carcinoma, Basal Cell</dc:subject>
               <dc:subject>Other subheadings::Other subheadings::Other subheadings::/drug therapy</dc:subject>
               <dc:subject>CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents</dc:subject>
               <dc:subject>Other subheadings::Other subheadings::Other subheadings::/adverse effects</dc:subject>
               <dc:subject>ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::carcinoma basocelular</dc:subject>
               <dc:subject>Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia</dc:subject>
               <dc:subject>COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos</dc:subject>
               <dc:subject>Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos</dc:subject>
               <dc:description>Secondary resistance; Locally advanced basal cell carcinoma</dc:description>
               <dc:description>Resistencia secundaria; Carcinoma basocelular localmente avanzado</dc:description>
               <dc:description>Resistència secundària; Carcinoma basocel·lular localment avançat</dc:description>
               <dc:description>The BOLT study was sponsored and funded by Novartis; this analysis was funded by Sun Pharma. Medical writing and editorial support were funded by Sun Pharma Europe B.V.</dc:description>
               <dc:date>2025-09-30T02:07:32Z</dc:date>
               <dc:date>2025-09-30T02:07:32Z</dc:date>
               <dc:date>2025-09-19T08:25:45Z</dc:date>
               <dc:date>2025-09-19T08:25:45Z</dc:date>
               <dc:date>2025-09</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
               <dc:identifier>http://hdl.handle.net/11351/13689</dc:identifier>
               <dc:relation>Journal of the European Academy of Dermatology and Venereology;39(9)</dc:relation>
               <dc:relation>https://doi.org/10.1111/jdv.20629</dc:relation>
               <dc:rights>Attribution-NonCommercial 4.0 International</dc:rights>
               <dc:rights>http://creativecommons.org/licenses/by-nc/4.0/</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:publisher>Wiley</dc:publisher>
               <dc:source>Scientia</dc:source>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>